Environmental factors influencing the risk of ANCA-associated vasculitis

Wen-Man Zhao, Zhi-Juan Wang, Rui Shi, Yu-Yu Zhu, Sen Zhang, Rui-Feng Wang and De-Guang Wang*

Department of Nephrology, The Second Hospital of Anhui Medical University, Hefei, China

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of diseases characterized by inflammation and destruction of small and medium-sized blood vessels. Clinical disease phenotypes include microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). The incidence of AAV has been on the rise in recent years with advances in ANCA testing. The etiology and pathogenesis of AAV are multifactorial and influenced by both genetic and environmental factors, as well as innate and adaptive immune system responses. Multiple case reports have shown that sustained exposure to silica in an occupational environment resulted in a significantly increased risk of ANCA positivity. A meta-analysis involving six case-control studies showed that silica exposure was positively associated with AAV incidence. Additionally, exposure to air pollutants, such as carbon monoxide (CO), is a risk factor for AAV. AAV has seasonal trends. Studies have shown that various environmental factors stimulate the body to activate neutrophils and expose their own antigens, resulting in the release of proteases and neutrophil extracellular traps, which damage vascular endothelial cells. Additionally, the activation of complement replacement pathways may exacerbate vascular inflammation. However, the role of environmental factors in the etiology of AAV remains unclear and has received little attention. In this review, we summarized the recent literature on the study of environmental factors, such as seasons, air pollution, latitude, silica, and microbial infection, in AAV with the aim of exploring the relationship between environmental factors and AAV and possible mechanisms of action to provide a scientific basis for the prevention and treatment of AAV.

KEYWORDS
AAV (ANCA-associated vasculitis), ANCA, air pollution, environmental risks, etiology, vasculitis
Introduction

Systemic autoimmune rheumatic diseases (SARDs) are a group of chronic autoimmune diseases that attack joints, bones, muscles, blood vessels, and related soft or connective tissues. Common SARDs include rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), primary Sjögren’s syndrome (pSS), systemic sclerosis (SSc), polymyositis (PM), dermatomyositis (DM), mixed connective tissue disease (MCTD), and systemic vasculitis. The onset of these diseases is more insidious. The course of these diseases are longer and require lifelong treatment, which severely threatens the physical and mental health of patients and has become an important public health problem (1–3). Systemic vasculitis, one of the most complex and challenging SARDs, is classified into large, medium, and small vessel vasculitis, mainly based on the size of the affected vessels (2022ACR/EULAR) (4). Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is an important part of the classification of vasculitis. AAV can affect many vital organs throughout the body, including the skin, kidneys, lungs, and brain. Additionally, untreated vasculitis progresses rapidly, causing irreversible damage to vital organs in the body and even death. Therefore, exploring the etiology and pathogenesis of AAV is crucial for early diagnosis and timely treatment.

AAV is a multisystem autoimmune disease that primarily involves small blood vessels throughout the body, and it is associated with the presence of ANCA in the serum (5, 6). ANCA, which was first identified by Davies in patients with necrotizing glomerulonephritis, is divided into two main types: cytoplasmic (C-ANCA) and perinuclear (P-ANCA), whose target antigens are proteinase 3 (PR3) and myeloperoxidase (MPO), respectively. Growing evidence confirms the pathogenic role of ANCA in AAV. Transfer of splenocytes from MPO-deficient mice immunized with mouse MPO into wild-type mice resulted in hyperimmune systemic vasculitis (7). Pendergraft et al. (8) demonstrated that complementary proteinase-3 (cPR3) antibodies may induce PR3-ANCA. Additionally, a new ANCA-targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associ cated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAMP-3, targeting human lysosome-associated membrane protein-2 (LAMP-2) has been described as a sensitive and specific marker for renal limited vasculitis (RLV). Rats produce LAMP-2 and LAM...
a prefix to the clinical phenotype of patients with established AAV (classified as PR3-ANCA disease and MPO-ANCA disease based on ANCA specificity) (26). MPA was associated with PR3-ANCA in 26% of cases and MPO-ANCA in 58% of cases (27). Whereas GPA was characterized by PR3-ANCA in 66% of patients and MPO-ANCA in 24% of patients. Studies have shown a higher rate of disease recurrence in PR3-ANCA and a higher mortality rate in MPO-ANCA disease. As an important clue to disease diagnosis, a positive ANCA does not necessarily confirm the diagnosis of AAV, whereas a negative ANCA does not exclude the diagnosis of AAV. For example, the presence of ANCA is absent in 40%–50% of patients with EGPA (28). Therefore, clinicopathological findings are the gold standard for the diagnosis of AAV.

**Epidemiology of AAV**

The introduction of ANCA testing in the 1990s has led to a marked increase in the incidence of AAV in recent years (12, 29). Currently, the prevalence of AAV is approximately 300/million, with an annual incidence of 13–20/million (11, 12). In Norway, the annual incidence of AAV is as high as 24.7/million. The incidence of adult GPA, MPA, and EGPA are 15.6/million, 6.5/million, and 2.7/million, respectively (12, 29). The overall incidence of AAV is increasing in Spain, Germany, and the UK (29, 30). Compared to incidence studies, relatively few studies on AAV prevalence have been reported. The overall prevalence of AAV per million adults reported in Norway in 2013 was 351; the prevalence of GPA, MPA, and EGPA were 261, 58.2, and 32.9, respectively (29). The increased prevalence of AAV may be related to factors, such as increased incidence, improved disease definition, and improved vasculitis registry systems.

Unlike other autoimmune diseases, AAV tends to develop in older and male patients. Studies in both the UK and New Zealand have confirmed that the peak incidence of AAV is at the age of 60–79 years (31–33). The reason for the tendency of AAV to develop in patients of advanced age is unclear. This may be related to advances in ANCA testing that have led to the detection of previously unrecognized AAV. Additionally, AAV is more common in men than in women (31, 34). Studies have shown a male prevalence to female prevalence ratio between 1.07:1 and 1.48:1 (31, 35–37). In Germany and New Zealand, no significant gender differences are present in the incidence of AAV. The reasons for the above occurrence are not clear.

**Immunology of AAV**

The mechanisms of the AAV autoimmune response have not been fully elucidated, but molecular mimicry and dysregulation of B and T lymphocytes have dominated the disease process. Activated B lymphocytes can produce pathogenic ANCA. Regulatory B (B reg) cells induce T cell differentiation into regulatory T (T reg) cells away from T helper 1 (TH1) and TH17 phenotypes and reduce B cell production of ANCA (38). Neutrophils are both targets of ANCA and mediators of endothelial injury. When exposed in response to infection or inflammation, the ANCA antigen-binding site can bind and activate neutrophils, leading to their degranulation and production of reactive oxygen species (ROS). It subsequently mediates vascular endothelial cell damage (18). Concurrently, intracellular signaling pathways are activated, resulting in changes in the expression and conformation of adhesion molecules, which promote the adhesion and migration of neutrophils in the vascular endothelium (39). Activated neutrophils undergo a specific form of cell death (NETosis), releasing neutrophil extracellular traps (NETs). NETs can mediate direct damage to the endothelium, transfer MPO/PR3 to the vascular endothelium and dendritic cells for antigen presentation, and activate the alternative pathway of complement. Tissue deposition of chemokines, PR3, and MPO lead to the recruitment of autoreactive T cells and monocytes, thereby aggravating vascular tissue damage. The therapeutic targets of NETs in different diseases mainly depend on the components of NETs. AAV-induced NETs were enriched in citrullinated histones, whereas SLE-induced NETs were enriched in oxidized mitochondrial DNA (40).

GPA is characterized by granuloma formation. Early granulomas are characterized by activated neutrophils forming microabscesses and scattered multinucleated macrophages. These macrophages release pro-inflammatory cytokines that promote the recruitment of neutrophils and monocytes from the blood to the lesion site. Recruited neutrophils release lytic enzymes and ROS upon encountering microorganisms and undergo lysis, leading to the formation of a necrotic core of the lesion. Advanced granulomas consist of a central area of necrosis with multinucleated giant cells at the margin, surrounded by dendritic cells, T lymphocytes, B lymphocytes, and plasma cells, forming a follicular structure of ectopic lymphoid tissue (41, 42). Lymphangiogenesis, defective transport capacity, and formation of ectopic lymph node-like structures are important mechanisms for the development of acquired immunity. Granuloma formation may be driven by B and T lymphocytes (43, 44). In patients with EGPA, elevated levels of TH2 cytokines, such as IL-4 and IL-5, are associated with eosinophilia. Eosinophils infiltrating tissues secrete eosinophilic granules, including major basic protein, eosinophilic neurotoxin, and eosinophilic cationic protein, that destroy vascular tissues.

**Environmental risk factors associated with AAV**

**Seasons**

Many studies have confirmed that the onset of AAV is strongly associated with seasonal changes, but the specific
results are inconsistent. Most studies (22, 23) report a higher number of patients with AAV hospitalized in winter, with a peak incidence during winter, and demonstrate a higher incidence of kidney damage in patients with AAV during winter. However, Mahr et al. (45) suggested that the incidence of AAV is significantly higher during summer, particularly in August. In studying the factors related to AAV relapse, Kemna et al. (46) showed that AAV is prone to relapse during autumn, accompanied by increased titers of ANCA-related immune markers. In contrast, no significant seasonal variation was found regarding the timing of symptom onset in a study of 445 patients with GPA (47). These findings cannot be merely limited to seasonal changes but also need to be extrapolated to specific causes or triggers.

The possible mechanisms that affect the incidence of AAV in different seasons may be different. Winter is a high incidence period for respiratory-related diseases, and infection may trigger the occurrence of AAV (48). Additionally, the level of vitamin D is an important factor affecting the pathogenesis of AAV. The active form of vitamin D is 1,25-dihydroxy vitamin D3 (1,25(OH)2 D3), which is an immunomodulator. Vitamin D and vitamin D-activating enzymes are widely present in various tissues, especially immune-related cells (Figure 1). The concentration of vitamin D in the body fluctuates with seasonal variations, and the concentration is the lowest during winter (49, 50). Källsch et al. (50) reported that patients with AAV had significantly lower serum vitamin D levels than healthy controls. Immune dysfunction caused by vitamin D deficiency may be involved in the development of AAV. The high incidence of AAV during summer may be caused by exposure to sunlight or air pollutants. Spring and summer are common seasons for various allergy-related diseases. Furthermore, AAV-related nasal disease may be caused by an immune response driven by Th2 cells. However, more studies are needed to confirm these speculations (30, 51, 52). Seasonal inconsistency may be due to differences in AAV disease subtypes, geographic regions, patient records, onset time deviations, and regional differences in medical levels in each study.

**Air pollution**

Air pollution has become a serious environmental problem, severely endangering public health (53–55). Air pollution is composed of a variety of gases and particles, including carbon monoxide (CO), sulfur dioxide (SO2), nitrates (NOX), ozone (O3), lead, toxic by-products of tobacco smoke, and particulate matter (PM). Fuel combustion is a major source of ambient air pollution. Combustion releases various pollutants, such as carbon oxides,
sulfur oxides, nitrogen oxides, polycyclic aromatic hydrocarbons (PAHs), and PM, and harmful metals, such as lead and cadmium, into the atmosphere. Additionally, transportation is an important source of ambient air pollution, which can produce a large amount of pollutants, such as PM, nitrogen oxides, CO, and polycyclic aromatic hydrocarbons. Studies have shown that air pollution is associated with various rheumatic immune diseases. Air pollutants may be involved in the induction of systemic inflammation and enhancement of autoimmunity, thereby inducing or aggravating autoimmune rheumatic diseases (56–58). For example, changes in the concentrations and types of air pollutants may affect disease activity in patients with SLE. In recent years, some studies have shown that air pollution may be related to the occurrence and development of AAV. Data from a survey on the prevalence of AAV disease in China (22) showed that CO exposure was positively correlated with AAV incidence, but air pollutants (PM2.5, PM10, other inhalable particulate matter, NO2, and SO2) had no significant correlation with AAV incidence (Table 1). Previous studies have found that CO has anti-inflammatory effects; therefore, the harmful effect of CO on vasculitis needs to be further explored (77). Nuyts et al. (65) found that exposure to hydrocarbons was not a risk factor for GPA and found no significant association between lead, cadmium, and GPA. In contrast, Pai et al. (66) found significantly higher mean hydrocarbon exposure in GPA and MPA cases. Albert et al. (51) found that heavy metal exposure can significantly increase the risk of GPA; these heavy metals are mainly cadmium, lead, and mercury. Subsequently, they found that the GPA population may be exposed to high levels of industrially generated contaminants, including trichloroethylene (TCE), vinyl chloride, methyl tertiary-butyl ether (MTBE), dichloroethene (DCE), and chromic acid (67).

AAV disease is an occupational hazard of agriculture, and the reason may be related to exposure to pollutants. Lane et al. (69) found that a history of organic solvent exposure may be associated with AAV, especially GAP. The same results were obtained in two other studies (70, 71). Studies in Scotland, Germany, and Canada showed that the incidence of AAV in rural areas is higher than that in cities. This may be related to environmental pollutants and pesticide exposure in remote areas (68, 72, 78, 79). Additionally, a large Swedish case-control study (73) found no association between occupation and GPA (Table 1). Unfortunately, these studies only reported the association between pollutants and AAV disease but did not investigate the mechanisms that influence disease.

Previous studies found that tobacco smoking is associated with the development of RA and SLE (80–84). However, findings on the relationship between smoking and AAV have been inconsistent. McDermott et al. (76) proposed that smoking is a risk factor for AAV disease, especially with MPO-ANCA. Yamaguchi et al. (75) found that current smoking status was associated with recurrence (Table 1). However, Haubitz et al. (85) found that smoking may have a potential protective effect against AAV disease. Additionally, studies have linked exposure to silica, tillage, or organic solvents to an increased risk of EGPA, whereas smoking is associated with a lower risk (74). The immunosuppressive effects of nicotine have been suggested as a potential explanation for these findings (86). A series of studies could not elucidate the effect of smoking on AAV disease (69, 70, 87). Current research on smoking and AAV risk has produced conflicting results, and further research is needed to examine the link between smoking and AAV disease progression.

Silicon dioxide

Silica is one of the most abundant minerals on earth, and exposure to silica dust has been identified as a risk factor for many SARDs, including SS, RA, SLE, and AAV (60, 88). Individuals working in agriculture, mills, drilling, painting, and textiles have been identified to have a greater risk of developing AAV disease (89). Multiple case reports (20, 21) have shown that continuous exposure to silica increases the risk of positive ANCA. Several studies have described cases of silica exposure and AAV. A 74-year-old patient with AAV developed fever and malaise after prolonged exposure to silica (90). Main and Wroe (91) described three cases of silica-exposed patients with AAV, two of whom still required dialysis after treatment. Analysis of the occupational histories of 16 patients with AAV revealed that patients with vasculitis were more likely to be exposed to silica than controls (61). Previous surveys on post-earthquake disease prevalence, such as the Kobe earthquake in Japan, the Great East Japan earthquake, and the Yunnan earthquake in China, showed that the incidence of AAV was higher than before (62–64). The change was attributed to the harmful effects of air pollution on the human body due to increased atmospheric levels of silica from the earthquake. Studies have confirmed the dose-related effects of silica exposure. A meta-analysis (60) showed that silica exposure was positively associated with AAV. A case-control study (59) suggested a 3.4-fold increased risk of ANCA serology positivity in individuals with occupational silica exposure. Only a few studies (92, 93) have proposed a relationship between sustained exposure to silica and AAV. However, research on the relationship between sustained exposure to silica and severity of AAV remains inadequate.

The mechanism by which silica causes AAV is unclear. A previous study (91) found that silica does not have a direct toxic effect on genetically susceptible individuals but rather enhances the immune response non-specifically, activates T cells and Treg cells, and leads to autoimmune dysfunction (Figure 1). With continued exposure to crystalline silica, the body produces inflammatory cytokines, including interleukin-1 (IL-1) and tumor necrosis factor-beta (TNF-β), leading to inflammation and eventual fibrosis (60). Silica can induce apoptosis of neutrophils, macrophages, and monocytes, and damaged cells release many proteolytic enzymes, leading to chronic
| Environmental factors | Year | Region | Study design | Participants | Main conclusions |
|-----------------------|------|--------|--------------|--------------|------------------|
| SiO₂                  |      |        |              |              |                  |
| Beaudreuil et al.     | 2005 | France | Case-control study | Patients with AAV | Silica exposure is dose-dependently associated with ANCA positivity. |
| Gomez-Puerta et al.   | 2013 | USA    | Systematic review and meta-analysis | Six studies | Exposure to silica increases the risk of AAV by 2.57 times. |
| Gregorini et al.      | 1993 | Italy  | Hospital-based case-control study | Patients with AAV | Seven of the 16 cases and one of the 32 controls had positive histories of jobs with exposure to silica dust. |
| Gupta et al.          | 2019 | India  | Case report | Patients with GPA | In a tuberculosis-endemic country, for patients presenting with diffuse alveolar hemorrhage (DAH), with history of silica exposure, differential diagnosis of ANCA-associated vasculitis must be considered. |
| Rao et al.            | 2020 | Australia | Case report | Patients with AAV | The relevance of occupational exposures in renal disease and the immune-stimulatory effect of silica. |
| Earthquake-related environmental exposures | | | | | |
| Yashiro et al.        | 1999 | Japan  | Case series | Patients with AAV | The frequency of MPO-AAV cases in the Kobe area has more than doubled each year since the earthquake. |
| Takeuchi et al.       | 2017 | Japan  | Retrospective population-based cohort study | Patients with MPO | The annual incidence of MPO-AAV doubled after the earthquake. |
| Faquhar et al.        | 2017 | New Zealand | Retrospective cohort study | Patients with AAV | No statistically significant difference in the incidence of AAV existed before and after the earthquake. |
| Other pollutants      |      |        |              |              |                  |
| Li et al.             | 2018 | China  | Retrospective cohort study | Patients with AAV | Carbon monoxide exposure was positively correlated with the frequency of AAV. |
| Nuys et al.           | 1995 | Belgium | Case-control study | Patients with GPA GPA AAV | The association between lead and cadmium and GPA was not significant. Exposure to hydrocarbons and welding fumes were not risk factors for GPA. |
| Pai et al.            | 1998 | UK     | Case-control study | Patients with AAV | The mean hydrocarbon exposure was significantly greater in cases than in controls. |
| Albert et al.         | 2004 | USA    | Case-control study | Patients with GPA GPA AAV | Mercury was associated with GPA. The association between CO and GPA approached statistical significance. |
| Albert et al.         | 2005 | USA    | Case series | Patients with GPA GPA AAV | This cluster of patients with GPA were potentially exposed to high levels of industrially generated contaminants. |
| Chung et al.          | 2022 | Australia | Retrospective study | Patients with AAV | No significant relationship existed between region and exposure to silica, solvents, metal, dust, farming, gardening, or sunlight. |
| Agriculture           |      |        |              |              |                  |
| Lane et al.           | 2003 | UK     | Case-control study | Patients with AAV | Farming exposure was associated with risk of GPA and MPA but not EGPA. High occupational silica exposure in the index year was a risk factor for AAV. The risk of MPA rises with occupations at intermediate or high silica exposure. |
| Stamp et al.          | 2015 | New Zealand | Case-control study | Patients with GPA GPA AAV | Farming was associated with an increased GPA risk. |
| Willeke et al.        | 2015 | Germany | Case-control study | Patients with GPA GPA AAV | Regular farm, cattle, and pig exposure were strongly associated with AAV. |
| Ayyegbusi et al.      | 2020 | UK     | National cohort study | Patients with AAV GPA GPA AAV | GPA (but not MPA) was positively associated with rurality. |
| Knight et al.         | 2010 | Sweden | Population-based case-control study | Patients with GPA GPA AAV | No general association existed between 32 selected occupations and GPA. |
| Smoking               |      |        |              |              |                  |
| Haubitz et al.        | 2005 | Germany | Cross-sectional cohort study | Patients with AAV | The prevalence of GPA/MPA among smokers was lower than among the general population. |

(Continued)
AAV, Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; EGPA, eosinophilic GPA.

**Inflammation and tissue fibrosis** (94). Another study (95) suggested that silica can induce the expression of MPO in the cell membrane of neutrophils and monocytes, causing ANCA-related autoimmune responses.

**Latitude**

A previous study (33) found that the incidence of AAV varies significantly with latitude, further supporting the influence of geographical region on AAV disease. Epidemiological studies (33, 34) have shown that the risk of GPA is high in the northern hemisphere of the earth, whereas the risk of MPA is high in the southern hemisphere. Quantitative changes showed marked changes, while the incidence of GPA and EGPA increased with increasing latitude and decreasing ambient UV radiation levels (24). Similarly, related studies have confirmed that the positive rate of PR3-ANCA decreases with increasing latitude and ultraviolet radiation intensity (96).

UV radiation is a sensitive factor that varies with latitude, and related studies have found a close relationship between UV radiation and immune diseases (46). UV radiation, which changes with latitude, is considered to be the actual cause of AAV. UV radiation is necessary for the skin’s synthesis of 1,25(OH)2 D3, which regulates immune system homeostasis. UV irradiation of the skin induces vitamin D synthesis, which in turn inhibits the proliferation of Th1 and Th17 cells and the production of cytokines. These changes cause the immune system to differentiate into Th2 cells, thereby enhancing the activity of CD24+, CD25+, and CD8+ cells. This is consistent with a mechanism mediated by Th1 and/or Th17 cells in the pathogenesis of GPA (97–99). This may explain why the association between MPA and UV light is not strong, since granulomas are not present in MPA. However, accurate estimation of the average amount of UV radiation in a region is challenging. The influence of immigration, clothing characteristics, skin color preferences, religious and cultural beliefs, and other factors need to be excluded, as well as the influence of dietary intake of vitamin D, related drugs, and other environmental factors on the final serum vitamin D level in each region. These challenges should be addressed in future studies.

**Microbial infections**

*Staphylococcus aureus*

Microbial infection is considered to be an important risk factor for the development of AAV. Intranasal *Staphylococcus aureus* (*S. aureus*) infection is most closely associated with AAV (25). The early symptoms of patients with GPA are mainly runny nose, nosebleeds, and other symptoms, because the most prominent feature of the disease is the granulomatous inflammation of the respiratory tract. *S. aureus* infection that colonizes the respiratory tract may trigger GPA disease activity (100). Previous studies (101) have found that the detection rate of *S. aureus* in patients with GPA is significantly higher than that in healthy individuals, and patients with GPA with chronic *S. aureus* infection have a significantly increased risk of recurrence. A randomized controlled trial (102) in the Netherlands showed that patients treated with trimethoprim/sulfamethoxazole (T/S, 960 mg three times a week) had a decreased recurrence rate by 66%. In contrast, prophylactic treatment of chronic *S. aureus* carriers with T/S did not reduce the risk of relapse (101). This may be related to factors, such as drug dosage and different bacterial detection methods (102). Further studies found that the imbalance in the proportion of various bacteria colonized in respiratory tract may contribute to the incidence of AAV. The proportion of *S. aureus* colonization in nasal samples of patients with GPA increased, but the diversity of the microbiome decreased (103–105). Current studies indicate that *S. aureus* is only related to the pathogenesis of GPA, but no obvious relationship seems to exist between *S. aureus* and the pathogenesis of MPA and EGPA.
The role of S. aureus in the pathogenesis of AAV may be as follows: (1) Superantigens of S. aureus directly stimulate B cells and T cells. Among them is the polyclonal activation of B cells by S. aureus cell wall components. Additionally, S. aureus may directly initiate neutrophils, leading to surface expression of PR3 (106). (2) S. aureus contains a highly homologous complementary form of the protein in humans. CPR-3 (105–201) acts as a protein complementary to the human autoantigen PR3 and elicits an autoimmune response (8). (3) The CpG motif of S. aureus may trigger B lymphocytes in the peripheral blood of patients in remission, leading to the production of ANCA and relapse of AAV (107). (4) The polypeptide 6-phosphogluconate dehydrogenase (6PGD) 391–410 encoded by the S. aureus plasmid is homologous to the previously determined immunodominant MPO-T cell epitope, and it is immunogenic in humans. Studies have shown that 6PGD induces MPO-related nephritis (108). (5) S. aureus-derived extracellular adhesion protein (EAP) and Staphylococcus peroxidase inhibitor (SPIN) can induce the body to produce ANCA (109). (6) S. aureus is an effective inducer of NETs, DNA extracellular complex, and antibacterial factors secreted by neutrophils. Exposure of ANCA antigens to the immune system can initiate an autoimmune response to AAV (110, 111).

**Viruses**

Epstein-Barr virus (EBV) infection is most closely related to various SARDs (112–116). Multiple case reports found that patients with AAV may develop anti-MPO antibodies following EBV infection. Treatment with glucocorticoids combined with ganciclovir can significantly relieve clinical symptoms and reduce viral load (117–119). Li et al. (120) found that anti-EBV capsid antigen antibodies and anti-EBV early antigen antibodies were significantly higher in the sera of patients with AAV than in healthy individuals. Treatment with glucocorticoids in combination with ganciclovir significantly relieved clinical symptoms and reduced viral load. Hepatitis B virus (HBV) and hepatitis C virus (HCV) may be triggers for SARDs. An Egyptian study (121) found 62.7% hepatitis C virus infection in 42 patients with AAV, and C-ANCA levels were significantly correlated with hepatitis C virus antibody levels. Lee et al. (122) found a significantly higher risk of relapse in anti-HBc-positive patients with EGPA. Resolved HBV infection may have an important impact on vasculitis activity at diagnosis and subsequent relapse after remission in patients with EGPA. Recently, ANCA has been identified in patients with coronavirus disease 2019 (COVID-19) infections, but relatively few cases have been reported (123, 124). Studies have proposed the involvement of the parvovirus B19, human herpesvirus, and hantavirus in the occurrence of AAV (122, 125, 126). However, these studies are few and have not found a significant correlation between these viruses and the development of AAV.

**Other microorganisms**

Few studies have been conducted on other microorganisms in AAV. A Japanese study (127) reported that Aspergillus infections, including Candida, Candida, and Fusarium, were found in patients with both allergic bronchopulmonary mycosis (ABPM) and EGPA. Kuwabara et al. (128) found that Mycobacterium tuberculosis infection and anti-tuberculosis drugs may be related to AAV. Fujita et al. (129) found that the positive rate of Chlamydia pneumoniae in patients with MPO-AAV was 33%. A Japanese report (130) described a woman who underwent total thyroidectomy, developed PR3-ANCA 3 months after surgery, and had a chronic infection with Tsukamurella pu monis. GPA often occurs in gastrointestinal mucosal lesions, and the study detected 25 cases of Helicobacter pylor i infection among 36 patients with GPA (131). Currently, the effect of these microorganisms on AAV is only speculative, and further large-scale studies are needed to verify.

**Other environmental risk factors**

**Drugs**

Drug-induced small vessel vasculitis is a small group of AAV disorders that still do not have a precise definition. Drugs that may be associated include hydralazine, allopurinol, propylthiouracil, phenothiazine, nitrofurantoin, methimazole, minocycline, phenytoin sodium, penicillamine, levamisole, cocaine, isoniazid, montelukast, erlotinib, and tofacitinib (86, 89, 128, 132–134). Among them, the incidence of AAV caused by anthyroid drugs is higher, especially propylthiouracil. The clinical manifestations of propylthiouracil-induced AAV disease are similar to those of primary AAV, whereas the disease severity is less severe and prognosis is better. After cessation of anthyroid drug use, symptoms of patients with AAV gradually resolve and ANCA titers decrease significantly (135). Treatment strategies for drug-induced AAV differ from those for primary AAV (136). In patients with mild symptoms, immediate discontinuation of the relevant drug can lead to disease remission. Patients with severe diseases should be treated aggressively. However, immunosuppressive maintenance therapy is often unnecessary (137). The mechanism of drug-induced AAV disease may be related to NETs (138). However, further studies are needed to verify the exact mechanism (132). NETs are associated with inflammation in various ways. NETs can directly induce endothelial damage and activate alternative complement pathways (139). Additionally, they are a major component of thrombosis. The relationship between NETs and ANCA seems to be bidirectional, a vicious circle (111, 140, 141).

**Vaccines**

The efficacy of vaccines is based on the ability of the host immune response to the antigen to elicit a memory T-cell response over a period of time. The influenza vaccine is
similar to the mechanism of AAV caused by recurrent AAV after vaccination is still a mystery and may be COVID-19 mRNA vaccine. The mechanism of new or receiving the COVID-19 mRNA vaccine, and patients with ANCA (151). However, this evidence originates from individual monocytes after vaccination may cause MPO-ANCA and PR3-ANCA (151). However, this evidence originates from individual case reports, and no specific mechanism has been explored.

Conclusion

Studies to identify modifiable environmental risk factors for AAV can provide insights into disease pathogenesis and can facilitate the development of preventive strategies, especially in those individuals at high risk. The current consensus is that multiple environmental and epigenetic factors interact in a complex manner. Different triggers and extent of their roles in disease activity may vary by subgroups (e.g., ANCA subtype, geographic region). Numerous epidemiological studies support the relationship between exposure to various environmental pollutants, UV radiation deficiency, and microbial infections and the risk of developing AAV. Other environmental factors, including seasonal changes, latitudinal changes, medications, and vaccinations may be associated with an increased risk of AAV. Further studies are needed to confirm these findings. Additionally, future studies on environmental factors and AAV susceptibility subgroups need to be advanced, and exposures throughout the life course should be considered comprehensively.

Author contributions

W-MZ, Z-J W and D-GW were part of the organizing committee of the workshop. W-MZ wrote the manuscript. Z-JW, RS, Y-YZ, SZ, and R-FW contributed to the revision of the initial draft of the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by grants from the Natural Science Foundation of Anhui Province (No. 2008085MH244 and No. 2008085QH426).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Roodenrijs NMT, Welsing PMJ, van der Goes MC, Tekstra J, Lafeber F, Jacobs JW, et al. Healthcare utilization and economic burden of difficult-to-Treat rheumatoid arthritis: A cost-of-Illness study. Rheumatol (Oxford) (2021) 60(4):1871–81. doi: 10.1093/rheumatology/keab078
2. Gairy K, Knight C, Anthony P, Hoskin B. Burden of illness among subgroups of patients with primary sjögren’s syndrome and systemic involvement. Rheumatol (Oxford) (2021) 60(4):1871–81. doi: 10.1093/rheumatology/keab078
3. Kalkan A, Hallert E, Berndt L, Husberg M, Carlsson P. Costs of rheumatoid arthritis during the period 1990–2010. A register-based cost-of-Illness study in Sweden. Rheumatol (Oxford) (2014) 53(1):153–60. doi: 10.1093/rheumatology/ket290
4. Robson J, Craven R, Ponte C, Sufiapah R, Craven A, Judge A, et al. 2022 American College of Rheumatology/European alliance of associations for rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis (2022) 81(3):315–20. doi: 10.1136/annrheumdis-2021-221795
5. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum (1994) 37(2):187–92. doi: 10.1002/art.1780370206
6. Jennette JC, Falk RJ, Hu P, Xiao H. Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Annu Rev Pathol (2013) 8:139–60. doi: 10.1146/annurev-pathol-011811-132453
7. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest (2002) 110(7):955–63. doi: 10.1172/JCI15918
8. Pendergraft WF, Preston GA3rd, Shah RR, Tropsha A, Carter CWJr., Jennette JC, et al. Autoimmunity is triggered by cpr-3(105-201), a protein complementary to human autoantigen proteinase 3. Nat Med (2004) 10(1):72–9. doi: 10.1038/nm968
9. Kain R, Matsu S, Eksner M, Binder S, Schaffer G, Sommer EM, et al. A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis. The lysosomal membrane glycoprotein Lmp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells. *J Exp Med* (1995) 181(9):2857–67. doi: 10.1084/jem.181.9.2857

10. Kain R, Eksner M, Brandes R, Siebering M, Cunningham D, Alderson CA, et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. *Nat Med* (2008) 14(10):1088–96. doi: 10.1038/nm.1874

11. Mohammad A, Jacobsson L, Mahr A, Sturff G, Segelmark M. Prevalence of wegener’s granulomatosis, microscopic polyangiitis, polyarteritis nodosa and churg-strauss syndrome within a defined population in southern Sweden. *Rheumatol (Oxford)* (2007) 46(8):1329–37. doi: 10.1093/rheumatology/kem107

12. Watts R, Hatemi G, Burns J, Mohamed A. Global epidemiology of vasculitis. *Nat Rev Rheumatol* (2022) 18(1):22–34. doi: 10.1038/s41584-021-00781-8

13. Wu L, Huang H, Cai M, Yuan T, Sheng Y. Antineutrophil cytoplasmic antibody-associated vasculitis update: Genetic pathogenesis. *Front Immunol* (2021) 12:624848. doi: 10.3389/fimmu.2021.624848

14. Lyons P, Rayner T, Trivedi S, Holje’ W, Watts R, Jayne D, et al. Genetically distinct subsets within anca-associated vasculitis. *New Engl J Med* (2012) 367(3):214–23. doi: 10.1056/NEJMoa1107835

15. Oates T, Salama A. Epigenetic modifications in anca-associated vasculitis: Potential for insights into disease pathogenesis and prediction of outcome? *J Am Soc Nephrol* (2007) 18(4):1011–3. doi: 10.1681/ASN.2006090998

16. Scott J, Hartnett J, Mockler D, Little M. Environmental risk factors associated with anca associated vasculitis: A systematic mapping review. *Autoimmun Rev* (2020) 19(11):102660. doi: 10.1016/j.autrev.2020.102660

17. Watts R, Hutton RH, Holdsworth SR, Kitching AR. Anca-associated vasculitis: Challenges and solutions 2014. *Rheumatology* (2017) 56(1):27. doi: 10.1093/rheumatology/kew413

18. Prendecki M, Pusey CD. Recent advances in understanding of the genetic factors in autoimmune kidney diseases: A systematic review. *J Autoimmun* (2015) 60(1):27. doi: 10.1016/j.jaut.2014.09.004

19. Gatenby PA, Lucas RM, Engel P, Ponsoby AL, Clements M. Antineutrophil cytoplasmic antibody-associated vasculitis: Could geographic incidence gradient and role of microbial influence on the risk of relapse at a rise of antineutrophil cytoplasmic antibody-associated vasculitis compared to systemic lupus erythematosus. *Rheumatol (Oxford)* (2016) 37(4):242–6. doi: 10.1093/rheumatology/kew413

20. Dönnell JL, Stevanovic VR, Fritimore C, Stampy LK, Chapman PT. Wegener’s granulomatosis in new zealand: Evidence for a latitude-dependent incidence gradient. *Intern Med J* (2007) 37(4):242–6. doi: 10.1111/j.1445-5994.2006.01297.x

21. Watts RA, Lane SE, Scott DG, Koldingsnes W, Nossent H, Gonzalez-Gay MA, et al. Epidemiology of vasculitis in Europe. *Ann rheum Dis* (2001) 60(12):1156–7. doi: 10.1136/ard.60.12.1156a

22. Pamuk O, Dönmez S, Calayır G, Pamuk G. The epidemiology of antineutrophil cytoplasmic antibody-associated vasculitis in northwestern turkey. *Clin Rheumatol* (2016) 35(3):2063–71. doi: 10.1007/s10067-015-3322-y

23. Berti A, Corne D, Crouzen C, Specks U, Matteson E. The epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in Olmsted county, minnesota: A twenty-year population-based study. *Rheumatol (Hoboken NJ)* (2017) 69(12):2338–50. doi: 10.1002/rheu.40313

24. Gonzalez-Gay MA, Garcia-Porrua C, Guerreiro J, Rodriguez-Ledo P, Iloca R. The epidemiology of the primary systemic vasculitides in Northwest Spain: Implications of the chapel hill consensus conference definitions. *Arthritis rheum* (2003) 49(3):388–93. doi: 10.1002/art.11115

25. Jennette JC, Falk RJ. B cell-mediated pathogenesis of anca-mediated vasculitis. *Semin immuneopathol* (2014) 36(3):327–38. doi: 10.1055/s-0034-1361437

26. Radford DJ, Loo NT, Hewins P, Nash GR, Savage CO. Antineutrophil cytoplasmic antibodies stabilize adhesion and promote migration of flowing neutrophils on endothelial cells. *Arthritis rheum* (2001) 44(12):2851–6. doi: 10.1002/1529-0131(200112)44:12<2851::aid-art473>3.0.co;2-2

27. van Dam LS, Kraai T, Kamerling SWA, Bakker JA, Scherer UH, Rablinski TJ, et al. Intrinsically distinct role of neutrophil extracellular trap formation in antineutrophil cytoplasmic antibody-associated vasculitis compared to systemic lupus erythematosus. *Rheumatol (Hoboken NJ)* (2019) 71(12):2047–54. doi: 10.1002/rheu.41047

28. Muller A, Holk-Ulrich K, Gross W. Granuloma in anca-associated vasculitides: Another reason to distinguish between syndromes? *Curr Rheumatol Rep* (2016) 18(12):369. doi: 10.1007/s11926-015-0376-5

29. Schönermarck U, Cernok E, Gross W. Pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis: Challenges and solutions 2014. *Nephrol Dial Transplant* (2015) 30 Suppl 1:S1–12. doi: 10.1093/ndt/gfu398

30. Cernok E, Trebaut A, Müller A, Wang G, Moosig F, Paulsen J, et al. Cytokine profiles in wegener’s granulomatosis: Predominance of type 1 (Th1) in the granulomatous inflammation. *Arthritis rheum* (1999) 49(4):742–50. doi: 10.1002/1529-0191(199904)49:4<742::aid-art18>3.0.co;2-i

31. Watts R, Lane S, Bentham G, Scott D. Epidemiology of systemic vasculitis: A ten-year study in the united kingdom. *Arthritis Rheumatol (Oxford England)* (2022) 74(6):589–96. doi: 10.1002/rheumatology/kez413

32. đã occurrence and role of microbial influence on the risk of relapse at a rise of antineutrophil cytoplasmic antibodies in vasculitis patients with renal involvement. *J Rheumatol* (2007) 34(12):2473–81. doi: 10.3899/jrheum.160066

33. Aries PM, Herlyn K, Reinhold-Keller E, Latza U. No seasonal variation in the onset of symptoms of 45 patients with wegener’s granulomatosis. *Arthritis rheum* (2008) 59(6):904. doi: 10.1002/art.23722

34. Delemer RE, McDonald TJ, Weiland LH. Wegener’s granulomatosis: Observations on treatment with anticoagulative agents. *Mayo Clin Proc* (1985) 60(1):27–32. doi: 10.1016/s0025-6196(12)65279-3

35. Peelen E, Knuppenberg S, Murtis AH, Theissen M, Smolders J, Tervaert JW, et al. Effects of vitamin d on the peripheral adaptive immune system: A review. *Autoimmun Rev* (2011) 10(12):733–43. doi: 10.1016/j.autrev.2011.05.002

36. Kálsch AJ, Peters A, Buhl B, Breedek A, Prem K, Schmitt WH, et al. Retinoic X receptor beta polymorphisms do not explain functional differences in vitamins d and a response in antineutrophil cytoplasmic antibody associated vasculitis patients. *Autoimmunity* (2009) 42(5):473–81. doi: 10.3899/jra.09.306347

37. Albert D, Clarkin C, Komornik J, Breitner CM, Berlin JA. Wegener’s granulomatosis: Possible role of environmental agents in its pathogenesis. *Arthritis rheum* (2004) 51(4):656–64. doi: 10.1002/art.20534
et al. Changes in the composition of the upper respiratory tract microbial 
335(1):16
granulomatosis.
Characterisation of the nasal microbiota in granulomatosis with polyangiitis.
doi: 10.1016/j.jaut.2018.10.005
(395)(1):45–8. doi: 10.1007/s10029-018-4088-0
351(2):339–45. doi: 10.1186/s12887-021-02812-y
Ann Rheum Dis (Hoboken NJ)
9(1):1703
Annals of Rheumatic Disease. 2019. 77(10):1448. doi:10.1186/s12887-021-02812-y
Ann Rheum Dis (Oxford England)
1950)
Characterisation of the nasal microbiota in granulomatosis with polyangiitis
et al. Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil 
1,25-dihydroxyvitamin D3 selectively modulates tolerogenic properties in
et al. A plasmid-encoded peptide from staphylococcus aureus induces anti-
5. doi:10.1126/science.1092385
6. doi:10.1038/s41467-019-11255-0
18. doi:10.1182/blood-2012-03-416156
Rheumatol (Oxford England)
Arthritis Rheumatol (Oxford England)
2018) 55(7):793–7. doi: 10.2169/internalmedicine.9599-22
128. Kuwabara G, Yamada K, Tanaka K, Nozuchi S, Imoto W, Shibata W, et al.
112. Heeringa P. Bacterial DNA motifs trigger anca production in anca-associated 
7. doi:10.1007/s00296-018-4043-z
113. Ban S, Goto Y, Kamada K, Takahama M, Watanabe H, Iwahori T, et al.
129. Kamai K, Kawai K, Ikari Y, Fujimoto S, Hashimoto K, Sato T, et al.
127. Ishiguro T, Takayanagi N, Takaka Y, Kagayama K, Kurashima K, Sugita Y.
72. doi:10.1093/rheumatology/kex001
118. Dutz JP, Benoit L, Wang X, Demetrick DJ, Junker A, de Sa D, et al.
53. doi:10.1007/s10029-018-4088-0
106. Kallenberg CG, Tadema H. Vasculitis and infections: Contribution to the 
A subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate.
J Immunol (Baltimore Md 1950)
121. Mohamed AB, Hefny HM, Safi-El-Islam M, Zaghloul AM, Khalaf S, Hassanzaden AB, et al.
110. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss 
111. Sangaletti S, Tripodo C, Chiodoni C, Guarnotta C, Cappetti B, Casalini P, 
119. Xu P, Lin S, Wei L, Shang W. Antineutrophil cytoplasmic antibody-associated 
120. Ban S, Goto Y, Kamada K, Takahama T, Maeda M, Shimizu H, Fujita Y, et al.
126. Tsukamurella pulmonis central venous catheter infection mimicking proteinase 3-antineutrophil cytoplasmic antibody (Pr3-Anca)-Associated vasculitis. 
50. doi: 10.1080/25785826.2020.1791403
124. Reiff DD, Meyer CG, Marlin B, Mannion ML. New onset anca-associated 
19. Heeren F, Huguet M, Lerebours C, Richardson T, Jacobs L, et al.
105. Guzmán J, Choi JH, Nahmias AJ, Bellanti JA, Bellanti JS. Neutrophilic 
51. Hromadko A, Engel C, Sehgal S, Grgurinovic M, Baumann J, et al.
98. Gorman S, Kuritzky LA, Judge MA, Dixon KM, McGlade JP, Mason RS, 
96. Arndt F, Hoffmann R, Lütgehetmann M, Dörner T, et al.
97. Penna G, Amachastegui S, Giarratana N, Daniel KG, Vulcano M, Sozzi S, et al.
9. doi: 10.3349/ymj.2006.47.4.475
101. Lamprecht P, Fischer N, Huang J, Burkhardt L, Lütgethethmann L, Arndt F, et al.
95. Lee S, Hayashi H, Maeda M, Chen Y, Matsuzaki H, Takei-Kumagai N, et al.
135. Schamp V, Verfaillie C, Bonny C, Vande Walle J, Rieu A, Dehousse J, Propothiyoracil-induced anca-associated vasculitis in a 14-Year-old girl. "Acta clinica Belgica (2015) 70(2):127–9. doi: 10.1179/229533714X1000009000
136. Grau RG. Drug-induced vasculitis: New insights and a changing lineup of suspects. *Curr Rheumatol Rep* (2015) 17(12):71. doi: 10.1007/s11926-015-0545-9

137. Chen M, Gao Y, Guo XH, Zhao MH. Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis. *Nat Rev Nephrol* (2012) 8(8):476–83. doi: 10.1038/nrneph.2012.108

138. Arneth B, Arneth R. Neutrophil extracellular traps (Nets) and vasculitis. *Int J Med Sci* (2021) 18(7):1532–40. doi: 10.7150/ijms.53728

139. Wang H, Wang C, Zhao MH, Chen M. Neutrophil extracellular traps can activate alternative complement pathways. *Clin Exp Immunol* (2015) 181(3):518–27. doi: 10.1111/cei.12654

140. O’Sullivan KM, Holdsworth SR. Neutrophil extracellular traps: A potential therapeutic target in mpo-anca associated vasculitis? *Front Immunol* (2021) 12:635188. doi: 10.3389/fimmu.2021.635188

141. Shida H, Hashimoto N, Kusuoka Y, Hattanda F, Ogawa Y, Hayashi T, et al. Anti-neutrophil extracellular trap antibody in a patient with relapse of anti-neutrophil cytoplasmic antibody-associated vasculitis: A case report. *BMC Nephrol* (2018) 19(1):145. doi: 10.1186/s12882-018-0953-y

142. Perez-Vilar S, Wernecke M, Arya D, Lo AC, Lufkin B, Hu M, et al. Surveillance for Guillain-Barré syndrome after influenza vaccination among U.S. Medicare beneficiaries during the 2017–2018 season. *Vaccine* (2019) 37(29):3856–65. doi: 10.1016/j.vaccine.2019.05.041

143. Norton B, Kon SP, Perera R, Hull R. Vaccine: Friend or foe? double seropositive vasculitis following influenza vaccination. *Oxford Med Case Rep* (2019) 2019(5):omt031. doi: 10.1093/omcr/omt031

144. Jeffs LS, Nitschke J, Tervaert JW, Peh CA, Hurtado PR. Viral rna in the influenza vaccine may have contributed to the development of anca-associated vasculitis in a patient following immunisation. *Clin Rheumatol* (2016) 35(4):943–51. doi: 10.1007/s10067-015-3073-0

145. Eindhoven S, Levels J, Huisman M, de Winter KB, Dalm V, Alwani R. Mpo-anca associated vasculitis with mononeuritis multiplex following influenza vaccination. *Allergy asthma Clin Immunol Off J Can Soc Allergy Clin Immunol* (2017) 13:49. doi: 10.1186/s13233-017-0222-9

146. Salem S, D’Amelio R. Could autoimmunity be induced by vaccination? *Int Rev Immunol* (2010) 29(3):247–69. doi: 10.3109/08830181003746304

147. Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. *Clin Rev Allergy Immunol* (2012) 42(1):102–11. doi: 10.1007/s12016-011-8294-7

148. Guimarães LE, Baker B, Perricone C, Shoenfeld Y. Vaccines, adjuvants and autoimmunity. *Pharmacol Res* (2015) 100:190–209. doi: 10.1016/j.phrs.2015.08.003

149. Izredine H, Bonilla M, Jhaveri KD. Nephrotic syndrome and vasculitis following sars-Cov-2 vaccine: True association or circumstantial? *Nephrol Dial Transplant* (2021) 36(9):1565–9. doi: 10.1093/ndt/gfab215

150. Nishioka K, Yamaguchi S, Yasuda I, Yoshimoto N, Kojima D, Kaneko K, et al. Development of alveolar hemorrhage after pfizer-biontech covid-19 mrna vaccination in a patient with renal-limited anti-neutrophil cytoplasmic antibody-associated vasculitis: A case report. *Front Med* (2022) 9:874831. doi: 10.3389/fmed.2022.874831

151. Baez E, Olgemöller U, Biggemann L, Buck C, Tampe B. Dual-positive mpo- and Pr3-Anca-Associated vasculitis following sars-Cov-2 mrna booster vaccination: A case report and systematic review. *Vaccines* (2022) 10(5):653. doi: 10.3390/vaccines10050653